Document is current
Any future updates will be listed below
-
Authors
Kaiser, Anne
Lysenko, Veronika https://orcid.org/0000-0002-6886-5444
Myburgh, Renier
Volta, Laura
Pellegrino, Christian https://orcid.org/0000-0001-7898-9988
Theocharides, Alexandre P. A. https://orcid.org/0000-0002-1535-8692
Christen, Deborah
Panse, Jens https://orcid.org/0000-0001-6316-3112
Bühler, Marco M. https://orcid.org/0000-0003-0850-3326
Arock, Michel https://orcid.org/0000-0002-3990-4408
Butterfield, Joseph
de Toledo, Marcelo A. S. https://orcid.org/0000-0003-4318-7381
Valent, Peter https://orcid.org/0000-0003-0456-5095
Zenke, Martin https://orcid.org/0000-0002-1107-3251
Brümmendorf, Tim H.
Manz, Markus G. https://orcid.org/0000-0002-4676-7931
- License Information
-
More Information
Article History
Received: 23 July 2025
Revised: 20 March 2026
Accepted: 14 April 2026
First Online: 7 May 2026
Competing interests
: MA: 1. Research grants from Blueprint Medicines, 2. Honoraria: AB Science, Blueprint Medicines and Thermo Fisher. JB: Licence fee by Millipore/Sigma for HMC-1. PV: 1. Research grant: AOP Orphan, 2. advisory board and consultancy honoraria: Novartis, Blueprint Medicines, Amgen, Cogent, Delbert, PentaBase, Daiichi Sankyo, Pfizer, AOP Orphan, Stemline. AK, VL, RM, LV, CP, APAT, DC, JP, MMB, MAST, MZ, THB, MGM declare no competing financial interests.
